Published online Oct 28, 2021. doi: 10.3748/wjg.v27.i40.6951
Peer-review started: February 4, 2021
First decision: March 6, 2021
Revised: March 17, 2021
Accepted: August 25, 2021
Article in press: August 25, 2021
Published online: October 28, 2021
Processing time: 265 Days and 6.3 Hours
Hepatic and gastrointestinal (GI) disturbances have been reported in patients with coronavirus disease 2019 (COVID-19) with variable prevalence according to disease severity and population characteristics. This could be due to direct severe acute respiratory syndrome coronavirus 2 invasion through the angiotensin-converting enzyme 2 receptors or indirect effects such as an uncontrolled immune response, drug-induced injury, or sepsis.
Comprehensive researches on hepatic and GI derangements in patients with COVID-19 are still lacking, and they are needed for better understanding of the underlying factors, clinical presentations, and disease outcome
We aimed to study the prevalence and severity of liver and GI derangements in Egyptian patients with COVID-19 infection and their relation to disease outcomes.
This multicentre cohort study was conducted on 547 COVID-19 cases from four quarantine hospitals during the period from April 15, 2020 to July 29, 2020. Clinical, laboratory features, fibrosis-4 (FIB-4) index, COVID-19 severity, and outcomes were recorded. Follow-ups were conducted until discharge or death.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were elevated in 26% and 32% of patients while elevations above 3 fold were recorded in 4.91% and 3.73% patients, respectively. Male gender, smoking, hypertension, chronic hepatitis C, and lung involvement were associated with elevated AST or ALT. FIB-4 was significantly higher in patients admitted to the intensive care unit (ICU), those with more severe COVID-19, and non-survivors. The independent variables affecting outcome were supplementary vitamin C intake, lung consolidation, ICU admission, and FIB-4 score > 3.25. GI symptoms were present in 60 (13.98%) patients. They were predominantly females with higher body mass index, and 50 (83.40%) patients had non-severe COVID-19.
Significant liver injury was uncommon among Egyptian patients with COVID-19. The independent variables affecting mortality were supplementary vitamin C intake, lung consolidation, ICU admission, and FIB-4 score.
Variables independently affecting mortality were supplementary vitamin C intake, FIB-4 score > 3.25, lung consolidation, and ICU admission. GI symptoms occurred in patients with non-severe COVID-19.